| Identification | Back Directory | [Name]
Benzenesulfonamide, 5-[4-(4-bromophenyl)-4,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-yl]-3-(butylamino)-2-phenoxy- | [CAS]
2417995-10-7 | [Synonyms]
COX-2-IN-24
Benzenesulfonamide, 5-[4-(4-bromophenyl)-4,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-yl]-3-(butylamino)-2-phenoxy- | [Molecular Formula]
C24H24BrN5O3S2 | [MOL File]
2417995-10-7.mol | [Molecular Weight]
574.51 |
| Hazard Information | Back Directory | [Uses]
COX-2-IN-24 is an orally active inhibitor of COX-2 with IC50 value of 0.17 μM, shows anti-inflammatory and low ulcerogenic activities. | [in vivo]
COX-2-IN-24 (Intraperitoneal injection; 9mg/100g; once an hour; 4 hours) shows anti-inflammatory activity in the carrageenan-induced rat paw edema model[1].COX-2-IN-24 (Oral gavage; 9mg/100g; once a day; 3 days) shows low ulcerogenic activity in the received 1% gum acacia (suspending vehicle) orally male albino rats model [1]. | Animal Model: | Mature male albino rats[1] | | Dosage: | 9mg/100g | | Administration: | Intraperitoneal injection; 9mg/100g; once an hour; 4 hours | | Result: | Exhibited a promising anti-inflammatory activity in the carrageenan-induced rat paw edema model. |
| Animal Model: | Mature male albino rats[1] | | Dosage: | 9mg/100g | | Administration: | Oral gavage; 9mg/100g; once a day; 3 days | | Result: | Exhibited low ulcerogenic activity in the received 1% gum acacia (suspending vehicle) orally male albino rats model. |
| [IC 50]
COX-2: 0.17 μM (IC50) | [References]
[1] Tarek S Ibrahim, et al. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on bumetanide scaffold. Bioorg Chem. 2020 Jul;100:103878. DOI:10.1016/j.bioorg.2020.103878 |
|
|